BI, Eureka Therapeutics Partner in Oncology Antibodies
Eureka Therapeutics Inc. and Boehringer Ingelheim have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology. Eureka Therapeutics Inc. is a privately held biotechnology company, headquartered in the San Francisco Bay area, focused on developing T cell immunotherapies for hematological malignancies and solid tumors. Its core technology platforms center around the discovery and engineering of fully human antibodies against intracellular targets via the MHCI (major histocompatibility) complex. The company is developing a pipeline of cancer therapeutics targeting intracellular oncogenes.
Eureka Therapeutics will apply its proprietary human sequence antibody libraries and its technology platform to identify antibodies recognizing intracellular proteins, which represent approximately 90% of cancer-specific targets. Cancer-specific peptides that can be displayed via the MHC-complex on the cell surface will be selected by Boehringer Ingelheim to develop cancer therapies. Boehringer Ingelheim will have the option to conduct further development and commercialization of the antibodies. Under the terms of the agreement, Eureka Therapeutics will receive an undisclosed upfront technology access fee and research funding for each program and may receive technical success fees, option exercise fees, and other downstream payments.
Source: Boehringer Ingelheim